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ABSTRACT
The majority of the human population is infected with JC polyomavirus (JCPyV), which
establishes an asymptomatic infection in the kidney of healthy individuals. In
immunosuppressed individuals, the virus spreads to the brain and attacks glial cells,
causing progressive multifocal leukoencephalopathy (PML), a fatal demyelinating
disease. With limited treatments available, an improved understanding of the virus-host
cell interactions during JCPyV infection is crucial for developing effective PML
therapies. JCPyV internalization into host cells requires the serotonin 5hydroxytryptamine type 2 (5-HT2) receptors. The mechanism by which the 5-HT2Rs
mediate viral entry has not yet been characterized, yet it is thought to occur by clathrinmediated endocytosis (CME). The objective of this research is to determine whether key
5-HT2R scaffolding proteins that mediate clathrin-dependent endocytosis are required for
JCPyV infection. Reduction of cellular adaptor protein 2 (AP2), adaptor protein 180
(AP180), and clathrin by siRNA significantly reduced JCPyV infection, yet inhibition of
calmodulin using a chemical calmodulin inhibitor had minimal effect on JCPyV
infection. Taken together, these findings suggest these specific 5-HT2R scaffolding
proteins are crucial for JCPyV infection. Additionally, this research is not limited to our
understanding of JCPyV viral pathogenesis, a significant human pathogen with the
potential to cause fatality, but can also be applied to understanding other neurotropic
viruses or other viruses that enter by CME.
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Introduction
Overview
Opportunistic pathogens have become a major concern in the realm of infectious disease.
These pathogens cause asymptomatic infections in healthy individuals and are capable of
causing severe and life-threatening infections in patients who are immunosuppressed (1).
JC polyomavirus (JCPyV) is an opportunistic pathogen that causes progressive multifocal
leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system
(CNS). Specifically, JCPyV causes cytolytic destruction of oligodendrocytes, the myelinproducing cells of the CNS (2). PML has a fatality rate of 90% within the first two years
of symptom onset (2). Currently, approximately 5% of individuals who are HIV-1+ are
affected by PML (1), and in the past decade, the number of PML cases has risen to nearly
1:500 in patients who are receiving natalizumab, an immunomodulatory therapy designed
to treat immune-mediated diseases, such as multiple sclerosis (MS) and Crohn’s disease
(1,2). Thus, as the number of individuals receiving immunomodulatory therapies
increases with the rise of immune-related diseases, the incidence rate of PML is
anticipated to also rise. PML is a severe, debilitating disease, with affected individuals
experiencing deficiencies in cognitive functioning and developing symptoms such as
paralysis (1). Unfortunately, there are currently no viable treatments for this disease.
The limited treatment options for PML underscore the importance of
understanding the crucial mechanisms of viral attachment and internalization that enable
the virus to engage and initiate infection in target host cells. The goal of this research is to
identify and characterize the role of the scaffolding proteins calmodulin, adaptor proteins
2 (AP2) and 180 (AP180), b-arrestin, and clathrin in JCPyV internalization. These
studies provide insight into the mechanism of non-enveloped viral entry, which can serve
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as a platform for the development of potential therapeutic targets for not only JCPyV and
viral-associated PML, but also for other important human viral pathogens.

Progressive multifocal leukoencephalopathy
Polyomaviruses are non-enveloped double-stranded (ds) DNA viruses that infect a broad
range of hosts in nature (3). JCPyV, a human-specific polyomavirus, is considered a
ubiquitous pathogen because 50-60% of healthy adults are seropositive (3). There are two
common strains of the virus found in humans: the archetype, non-pathogenic strain that
can be isolated from the kidney and the PML-type, pathogenic strain that can be isolated
from the brain of PML patients. During an asymptomatic kidney infection, the virus can
undergo periods of reactivation and can be shed in the urine. Furthermore, JCPyV has
been detected in untreated wastewater, suggesting that it is contracted through an oral
route (1). JCPyV establishes a lifelong, persistent infection in the kidney and B cells of
bone marrow (4). The majority of infected patients are asymptomatic due to an effective
immune response to the infection in the kidney. However, JCPyV can undergo
reactivation when seropositive adults become severely immunosuppressed and the virus
spreads from sites of persistence to secondary sites of infection, including the CNS. In the
CNS, JCPyV infects glial cells, astrocytes and oligodendrocytes, and causes cytolytic
destruction of critical myelin-producing oligodendrocytes, which ultimately leads to PML
(5).
PML is diagnosed in a clinical setting through a cranial MRI (Fig. 1)
demonstrating characteristic white matter lesions in the subcortical area of the brain with
no mass effect, which indicates the absence of tumors (6). The characteristic white
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lesions observed on an MRI (Fig. 1)
indicate areas of myelin loss. A second
routine method for confirming PML
diagnosis is the presence of JCPyV
DNA in the cerebrospinal fluid (CSF)
through polymerase chain reaction
(PCR) (6). Most clinicians consider the
presence of white matter lesions on the

Figure 1: PML lesions and spread.
Magnetic resonance image (MRI) of development
of PML lesions over a two-month period. Red
arrows indicate areas of brain lesion (9). Used
with permission from ASM.

MRI and the presence of JCPyV DNA in the CSF to be sufficient to diagnose the patient
with PML (6). These two methods alleviate the need for a much riskier and more invasive
method of determination, such as a brain biopsy.
There are several specific populations that are at risk of developing PML (7), with
the two largest being those infected with the human immunodeficiency virus (HIV-1+)
and those with multiple sclerosis (MS) who are taking natalizumab as an
immunosuppressive treatment (7). Additionally, there are distinctions between these
populations regarding how individuals become immunosuppressed (i.e., a virus or an
immunomodulatory therapy). Patients who are immunosuppressed by HIV-1 infection
tend to have PML symptoms associated with weakness, speech abnormalities, and gait
abnormalities (8). By contrast, those who have natalizumab-induced PML tend to suffer
from cognitive disorders, motor abnormalities, and visual defects (8). It has been
suggested that this could be due to the fact that the lesions of natalizumab-induced PML
patients are primarily monofocal and develop in the frontal lobe (8). In comparison, HIV-
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1 induced PML lesions tend to be multifocal, meaning they are in multiple lobes of the
brain (8).
The most at-risk population is the HIV-1+ population, which constitutes
approximately 80% of annual PML cases (7). Unfortunately, there are no effective
clinical treatments for PML. The only partially effective course of action is immune
constitution. In HIV-1+ patients, the immune system is deficient and the pathogenic
strain of JCPyV is capable of spreading to the brain (7). Currently, the common treatment
for HIV-1 is highly active antiretroviral therapy (HAART). HAART is a combination of
anti-viral drugs that treat the HIV-1 infection and restore the immune system function in
patients who are immunosuppressed. Before the development of HAART, PML occurred
in 3-7% of all HIV-1 cases, accounted for 18% of all fatal HIV-related CNS infections,
and had a 95% mortality rate (9, 10). Since the development of HAART, the mortality
rate has fallen from 95% to 30% within one year of symptom onset and down to 60%
within two years of symptom onset in HIV-1+ patients (7). The incidence of PML has
also substantially decreased since the introduction of HAART. In a yearly representation,
the incidence of PML in HIV-1+ patients has decreased over time, from 14.8 cases per
1,000 in 1996 to 2.6 cases per 1,000 in 2005, and further, to 0.8 cases per 1,000 in 2011
(11).
The second largest population at-risk for PML are patients who are receiving
immunomodulatory therapies for immune-related diseases. The highest incidence of PML
in this population is among individuals with MS under treatment with the drug
natalizumab (11). This drug is a humanized monoclonal antibody that blocks autoreactive
T cells from trafficking to the brain and attacking myelin, a process that constitutes the
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underlying etiology of MS (7). However, the lack of T cells trafficking to the brain
results in decreased immune surveillance and is suggested to result in JCPyV reactivation
in the kidney and spread to the CNS, causing PML (8,9,11). Since 2005, there have been
over 711 reported cases of PML development in patients receiving natalizumab treatment
(7). For patients who developed PML from natalizumab treatment, the recommended
treatment is to stop taking the medication in an effort to reconstitute the immune system.
However, removal of the therapy can cause PML-immune reconstitution inflammatory
syndrome (PML-IRIS), an overwhelming inflammatory response that can result in
neurological worsening, long-term debilitation, and is often in itself, fatal (11).
Immunomodulatory drugs with life-threatening risks like PML are required by the FDA
to include a “black box warning” in the prescribing information (12). Natalizumab has a
black box warning but is regularly prescribed for MS. Even new drugs that have recently
come to market that have had no incidence of PML development during the extensive
FDA trial programs, still list PML in a black box warning to inform the consumer that
there is a chance of life-threatening side effects.

JCPyV attachment and entry
The first step in the infectious life cycle of viruses is attachment to cell surface receptors
and subsequent entry into host cells (13). The majority of polyomaviruses studied to date
use a sialic acid receptor to bind to the surface of target cells (13). JCPyV binds to host
cells via interactions of the outer capsid protein, viral protein 1 (VP1) with the α2,6linked glycan, lactoseries tetrasaccharide c (LSTc) receptor motif (13). There is some
evidence that JCPyV uses a clathrin-mediated endocytotic pathway that involves cell
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surface serotonin hydroxytryptamine (5-HT)2 family of receptors (14,25,27). Following
endocytosis presumably into a clathrin-coated pit, then trafficking to an endosome, the
enclosed vesicle traffics through the endocytic compartment to the endoplasmic reticulum
where partial uncoating occurs through the endoplasmic-reticulum-associated protein
degradation pathway (ERAD) (15). The partially uncoated virion subsequently traffics to
the nucleus where the virus is completely uncoated and the double stranded DNA
genome can be transcribed and replicated. JCPyV has temporal gene regulation;
expression of early gene T-antigen (T-Ag) drives genome replication and the production
of the late capsid structural viral
proteins 1, 2, and 3 (VP1, VP2,
VP3) (15). Following replication,
the capsid is assembled around
newly replicated genomes and
virions are packaged and released
from the cell.
Figure 2: JCPyV lifecycle. Attachment to host cells is
mediated through the viral capsid protein, VP1, which
interacts with the cell surface sialic acid receptor, LSTc.
After attachment, the virus is thought to be internalized
through interaction with the serotonin receptors 5-HT2Rs
via clathrin-mediated endocytosis. Clathrin-coated pits
can fuse with the early endosomes and transport the virus
to a caveolin-1+ vesicle and then to the ER. JCPyV is
partially uncoated in the ER before trafficking to the
nucleus where transcription, replication, and viral
assembly occurs. Mature virions are released from the cell
through cell lysis (1). Used with permission from ASM.

All subtypes of the 5-HT2
serotonin receptor family; 5-HT2A,
5-HT2B, and 5-HT2C, rescue JCPyV
infection in non-permissive cells
and enhance entry into cells, but the

mechanism by which this occurs remains unclear (4, 17). Previous studies have suggested
that JCPyV does not interact with the extracellular loops of 5-HT2Rs on the cell surface
((13,14) and Atwood Lab, unpublished results)). Thus, the 5-HT2 serotonin receptors play
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a critical role in JCPyV entry, yet the specific mechanism by which these receptors
facilitate viral entry remains unclear.

Serotonin receptors
Serotonin receptors of the 5-HT2 subfamily are important neurotransmitter receptors in
the brain, nervous system, and peripheral tissues (16). The 5- HT2 receptors are seven
transmembrane-spanning G protein coupled receptors (GPCRs) with three extracellular
loops and three intracellular loops.
The intracellular loops contain
specific binding domains for G
proteins and other scaffolding
proteins that when bound activate
cellular endocytosis and signaling
(16). After activation by ligands,
Figure 3: 5-HT2Rs activation and signaling. Following
the activation of the receptor, classical GPCR signaling is
associated with calmodulin recruitment. b-arrestin
recruitment causes uncoupling of the G protein through
desensitization of the receptor. The uncoupling event leads
to clathrin-mediated endocytosis. Clathrin-mediated
endocytosis requires the scaffolding proteins clathrin,
AP2, AP180, dynamin, and b-arrestin. This internalization
is associated with calmodulin-receptor signaling cascades
that promote the MAPK-ERK cascade, which results in an
increase in activation and nuclear transcription factors
(19). Image courtesy of Dr. Melissa Maginnis.

5-HT2Rs can activate two distinct
signaling pathways, a G-protein
coupled mechanism, and a barrestin mediated signaling
pathway, both of which converge
on the activation of the mitogen-

activate protein kinase pathway (MAPK) (Fig. 3). Additionally, desensitization of the
receptor and subsequent G-protein uncoupling also activates calmodulin; the reaction
cascade causes a calcium flux from the ER and further binding and stabilization of
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calmodulin to the serotonin receptor (18). This activation allows calmodulin to also
activate the MAPK pathway to stimulate downstream signaling (16) with the MAPK
pathway acting as a kinase cascade that results in the activation of extracellular signal
regulated-kinases (ERK), a transcription factor known to be crucial for JCPyV infection
(1). 5-HT2 receptor antagonists are utilized in the treatment of neurological disorders,
including mood disorders like depression, (18) and thus serve as a potential target as a
JCPyV and PML therapeutic. However, it is essential to first understand the exact
mechanism by which JCPyV is utilizing the 5-HT2Rs to determine which drugs can be
put forward in testing based on their exact target.
Previous research has demonstrated that the 5-HT2A, 5-HT2B, and 5-HT2C receptors
are crucial to JCPyV infection (4). These receptors only have a 50% sequence identity,
but have key intracellular motifs that are conserved throughout (4). The 5-HT2AR
contains two calmodulin (CaM)-binding domains, referred to herein as domain 1 and
domain 2. CaM is a ubiquitous calcium (Ca2+) binding protein sensor, as it is activated
and regulated by Ca2+ binding. CaM has four Ca2+ binding sites. Ca2+ binding causes a
conformational change that
activates CaM to serve as a
secondary messenger. Once
Figure 4: 5-HT2Rs conserved intracellular motifs. Key
intracellular proteins that bind these motifs are highlighted:
calmodulin binds CaM motifs, b-arrestin binds ASK motifs,
and clathrin binds NPXXY motifs.

activated, CaM can bind to
specific sites on the serotonin 5-

HT2 receptors (14). The 5-HT2A receptor contains four intracellular motifs that are
important to clathrin-mediated endocytosis. The (Ala-Ser-Lys) ASK and (Asn-Pro-any
amino acid (X)-X-Try) NPXXY domains serve as two potential binding sites for the
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CME associated protein, b-arrestin (17). The two CaM-binding sites in the intracellular
loops of the receptor consist of a 1-8-14 motif (domain 1) and a 1-10 motif (domain 2)
with hydrophobic residues and potential CaM binding sites at positions 1, 8, 10, and 14
(14) (Fig. 4). These motifs undergo a conformational change when bound by CaM that
stabilizes the receptor on the cell surface to allow for interaction with ligands via
receptor-mediated endocytosis, thus activating signaling events (16,17,18). Therefore, it
is expected that the presence of serotonin receptors on the surface of the cell is key to the
internalization and subsequent infection by JCPyV.
The b-arrestin ligand signaling pathway is activated by viral attachment to the cell
and causes the uncoupling of the G-protein from the serotonin receptor (17). The
uncoupling event is thought to be facilitated by the binding of calmodulin and the
activation of b-arrestin (19). The activation of b-arrestin facilitates the internalization of
the 5-HT2A receptor via clathrin-mediated endocytosis. Clathrin-mediated endocytosis
requires the recruitment of endocytic scaffolding proteins, such as AP2 and clathrin. In
turn, these proteins stimulate downstream signaling cascades that promote the activation
of cellular transcription (Fig. 2). Preliminary data from the Maginnis Laboratory has
shown that b-arrestin and the MAPK pathway are crucial for JCPyV infection.
Understanding how JCPyV is able to tip the activation of the serotonin receptor away
from the G-protein coupled signaling and towards the b-arrestin mechanism is essential
to understanding how drugs could be used to target 5-HT2Rs signaling pathways and
serve as effective therapeutics.
In an attempt to treat PML, clinicians have prescribed chemical antagonists that
target the reuptake of serotonin, such as selective serotonin reuptake inhibitors (SSRIs) in
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off-label treatment regimens. Several studies have assessed the use of different drugs that
target serotonin receptors in open label or anecdotal PML studies. One serotonin
antagonist that has been tested is the antidepressant mirtazapine. Mirtazapine has been
shown to selectively inhibit 5-HT2 and 5-HT3 receptors (20) and block JCPyV infection
in human glial cells (21). Reports of these anecdotal trials demonstrate that mirtazapine
treatment has varying degrees of efficacy in PML patients. There is evidence that
mirtazapine can improve the prognosis of patients who are diagnosed with PML. Indeed,
many studies have shown a significant decrease in the neurological deterioration and
detectable viral loads in the blood and CSF (22). On the other hand, reports have yielded
results that suggest mirtazapine is largely ineffective. In these studies, patients’
conditions rapidly deteriorated despite being treated with the 5-HT2R antagonist, and
there were no remarkable MRI changes in the infected patients (23). Thus, it is
questionable whether or not mirtazapine alone is an effective treatment of PML, but
studies have shown that it can be more effective when used with an anti-parasitic drug,
mefloquine, which has been shown to decrease JCPyV replication in vitro
(7). Mefloquine, a treatment for malaria, has been shown to be effective in treating
individuals with PML by causing a decreased JCPyV infection after the virus has entered
the cell (24,25,26). Taken together, these results suggest that mirtazapine may be
efficacious in preventing cell-to-cell spread of JCPyV by blocking infection of new cells
while mefloquine may be capable of treating underlying JCPyV infection where infection
has already been established. While the reports for use of mirtazapine and mefloquine are
promising, the conflicting evidence between these reports suggests that further
investigation and exploration is needed in determining the method of JCPyV-mediated
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infection by 5-HT2Rs. There should also be continued exploration of off-label use of
approved therapies in the treatment of JCPyV and PML.

Clathrin-mediated endocytosis
JCPyV is a non-enveloped virus; it must traverse the host cell membrane in order to
establish infection and is unable to fuse with the membrane like enveloped viruses (27).
Therefore, the virus must be internalized via a cellular endocytic pathway such as
clathrin-mediated endocytosis, micropinocytosis, or caveolin-dependent endocytosis (27).
It is proposed that JCPyV uses clathrin-mediated endocytosis for viral entry because
chemical inhibitors of clathrin-mediated endocytosis, including chlorpromazine, limit JC
virus infection (27). However, the mechanism by which this occurs is not well
understood because chlorpromazine has been shown to act as an antagonist of serotonin
receptors (25). CME is a process that is inherent to all cells as a method of internalizing
host factors that are needed for homeostasis and proliferation. Further, it is unknown
whether JCPyV-mediated CME occurs through direct virus-host interactions with the 5HT2 receptors. Previous literature has shown that JCPyV infection of host glial cells
requires the internalization of the CME associated protein, epidermal growth factor 15,
eps15 (27). There is additional evidence that that dominant-negative eps15 mutants
inhibit clathrin-dependent endocytosis (27). The dominant negative mutants also caused a
decrease in JCPyV internalization, further demonstrating that JCPyV likely enters the cell
in a clathrin-mediated fashion. This method of entry is different than its most closely
related polyomavirus, SV40. Even though they are very similar, SV40 uses sialic-acidcontaining ganglioside receptors and enters via a non-clathrin mediated mechanism (27).

11

Clathrin-mediated endocytosis is a complex and diverse cellular entry pathway
and has been chiefly reported to require cellular scaffolding proteins AP2, AP180, and
clathrin. However, activation of proteins involved for internalization is ligand-specific
and may vary based on the receptor utilized in addition to receptor-ligand activation.
Both AP2 and AP180 are able to bind to b-arrestin and recruit clathrin to the cell surface
(26). The classical view is that CME is initiated by the recruitment of AP2 to the plasma
membrane of the cell (28) and acts in conjunction with AP180 to attract clathrin for the
invagination of the receptor and virus (Fig. 5). This view is supported by research that
found that the mutation
of AP2 binding sites in
the eps15 protein
significantly decreased
the infection of a virus
Figure 5: Clathrin-mediated endocytosis. Ligand binding to receptors
leads to recruitment of AP2 and clathrin to the plasma membrane
(Binding/Recruitment). Membrane curvature forms a pit inside the cell
(Invagination/Maturation). Scission by dynamin causes internalization
of cargo in a clathrin-coated vesicle (36)) Used by permission from
MBInfo.

that uses CME (29). It
has been shown that
the use of siRNA

against the µ2 subunit of AP2 showed a significant decrease in the formation of clathrin
coated pits and vesicles, as the µ2 subunit contains a conserved motif capable of
interacting with GPCRs and facilitating CME pit formation (28). This indicates that AP2
is an important scaffolding protein capable of interacting with b-arrestin and can limit
CME, but it is not the only scaffolding protein that is crucial for CME.
AP180 is thought to act in a combinatorial manner with AP2 in clathrin
recruitment to the membrane of cells, yet the mechanism is not well understood (30).
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Studies have demonstrated that AP2 and AP180 colocalize and potentiate the binding of
clathrin to clathrin-coated vesicles (30) There is additional evidence that AP180 is four
times more efficient and effective at recruiting and binding to clathrin (28). Even though
AP180 is four times more effective at binding to clathrin, it has been shown that AP2 and
AP180 work together and are most effective when colocalized on the clathrin-coated
vesicle (30). Similar to AP2, the reduction of one protein does not completely abolish the
presence of clathrin-coated vesicles, likely indicating that the APs are capable of
recruiting clathrin in the absence of the other.
The most important protein for CME is clathrin itself. Upon recruitment of AP2
and AP180 to the plasma membrane, clathrin is recruited to the membrane to serve as an
outside coat for the vesicle (29). Interestingly, clathrin does not directly interact with the
invaginating membrane or the activated receptor, but has direct interactions with
scaffolding machinery around the pit. Once the vesicle is internalized into the cell, the
clathrin coat detaches and the contents of the vesicle become accessible to the cellular
endocytic pathway. It has been shown that the abolishment of the heavy chain of clathrin
causes a significant reduction in the presence of clathrin-coated vesicles in cells (30).
This finding demonstrates that clathrin is crucial for clathrin-mediated endocytosis. If
JCPyV requires clathrin-mediated endocytosis for infectious entry, then the abolishment
of any of these proteins in vitro will likely impact infection.

Research goals
The research discussed in this thesis explores the role of CME-scaffolding proteins and 5HT2R-protein interaction domains in JCPyV infection of human glial cells, resulting in
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JCPyV entry limitation by the abolishment of the clathrin-mediated scaffolding proteins
AP2, AP180, and b-arrestin, but not by the limitation of calmodulin. Entry was further
prevented by degrading clathrin, the key protein involved clathrin-mediated endocytosis.
These studies were conducted to further build on published literature and unpublished
work in the Maginnis Laboratory, which demonstrate that JCPyV is internalized into its
human host cells through clathrin-mediated endocytosis. This information will contribute
to the broader understanding of non-enveloped viral entry through clathrin-mediated
endocytosis. In addition, this research will provide new information about JCPyV entry
and possible mechanisms that can be targeted in the development of new antiviral
therapies.

Materials and Methods
Cell culture maintenance
A Lab Gard II laminar flow hood was used to limit contamination while conducting cell
culture experiments. SVG-A and HEK293A (Human Embryonic Kidney) cell lines were
used and cultured in T75 flasks that were grown in a humidified incubator at 37°C with
5% CO2. Both lines were passaged upon viewing approximately 90% confluence under
an inverted microscope. The SVG-A cell line was cultured in Minimum Essential
Medium (MEM) supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin (P/S) (Mediatech, Inc.), and 0.2% plasmocin (Invivogen).
HEK293A cells were cultured in similar conditions, except Dulbecco’s Modified Eagle
Medium (DMEM) were used in place of MEM. Both lines are adherent and were
detached by a 5-minute incubation at 37ºC with 4ML of 0.5% trypsin-EDTA (Gibco by
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Thermo Fischer Scientific). Following incubation, 9mL of fresh media was added to the
flask. The media, now containing the detached cell line was transferred to a 15mL conical
tube. The tube was centrifuged at 2,000 rpm for 5 mins. Pelleted cells were resuspended
in fresh complete growth media and divided to a new flask based on the desired growth
period. The new flask was then cultured in a humidified incubator at 37ºC and 5%
humidity until reaching confluence; at that time the process was repeated.

JCPyV and SV40 infection
Cells were treated with a chemical inhibitor or transfected with siRNA, before media was
removed and the cells were infected with JCPyV or SV40 (MOIs indicated in Figure
Legends). Viral infection was conducted in MEM with 2% FBS and no antibiotics in a
200µL volume. After a 1-hour incubation at 37ºC, cells were fed with 1mL of complete
MEM and allowed to incubate at 37ºC for 72 hrs before being fixed and stained by
indirect immunofluorescence.

Calmodulin inhibition
Calmidazolium chloride (Santa Cruz Biotechnology) was reconstituted in DMSO and
used at indicated concentrations. SVG-A cells were plated at 2.5x104 cells per well in a
24 well plate overnight. Upon 70% confluency, cells were treated with indicated
concentrations of inhibitor for 3 hrs prior to infection. Cells were immediately infected
after the pre-treatment with JCPyV (MOI of 1FFU/cell) in MEM containing 2% FBS and
incubated at 37ºC for 1 hour. After the incubation, cells were fed with 1mL of room
temperature MEM with 10% FBS and 1% P/S, incubated for 72 hrs at 37ºC, then fixed
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and stained by indirect immunofluorescence. Infection was quantified by the number of
VP1 positive nuclei in a visual field.

Indirect immunofluorescence
Following infection, cells were washed once with 1xPBS then fixed in ice cold methanol.
Fixed cells were incubated at -20ºC for greater than 10 mins before staining. After
incubation at -20ºC, cells were washed with 1xPBS 3 times for 10 mins each followed by
a 15-minute incubation with PBS-0.5% TX100 for permeabilization of the cellular
membranes. Cells were stained with a primary antibody, PAB597 (1:10) a hybridoma
supernatant that produces a monoclonal antibody against JCPyV VP1 (33) and was
generously provided by Ed Harlow. A secondary anti-mouse Alexa Fluor 488 antibody
(Thermo Fisher Scientific) was used to detect VP1+ cells. Cells were quantified for
infectivity by fluorescence microscopy by counting VP1+ cells in at least 5 visual fields
per well in triplicate wells for 3 separate experiments. Expression of VP1 was observed
under a 10x objective using a Nikon Eclipse Ti epifluorescence microscope. Percent
infection was quantified by the number of VP1+ nuclei per visual field divided by the
number of DAPI positive nuclei in the same field. The number of DAPI positive cells
were quantified using a binary created in the Nikon NIS-Elements Basic Research
software (Version 4.5), controlling for equal diameter and circularity of DAPI-stained
nuclei based upon threshold fluorescence. The average percentage of infected cells was
then normalized to the EGFR control siRNA. Significance was determined using a
Students’ t-test (Microsoft Excel).
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Flow cytometry to measure serotonin receptor expression
HEK293A cells were transfected with mutated 5-HT2A serotonin receptors in a 6 well
plate (0.5e6 cells per well) and allowed to grow overnight to 100% confluence. Media
was aspirated from the wells and all of the wells were washed with 1xPBS. The cells
were then incubated in Cellstripper (Corning). Cells were pooled in 1.5mL
microcentrifuge tubes, pelleted at 2500 rpm for 5 mins at 4ºC, and washed with PBS.
Cells were incubated with a 1:250 dilution of the 5-HT2A receptor primary antibody, SR2A (Santa Cruz Biotechnology), for 30 mins at 4ºC. After the incubation, the cells were
pelleted at 2500 rpm for 5 mins and washed 3 times with PBS. A total of 100µL of the
cells were transferred to a new tube and were incubated with the secondary antibody,
anti-rabbit Alex Fluor 488 antibody (Thermo Fisher Scientific). Incubation was
conducted on ice for 2 hrs with agitation of the solution every 15 mins. Cells were
washed, pelleted by centrifugation at 2500 rpm, and resuspended in 500µL of PBS. Cells
were analyzed for 5-HT2A receptor expression of the cell surface using a BD FACSCanto
(BD Biosciences) equipped with a 488 laser excitation line (Benton, Dickinson, and
Company). The data generated by this experiment were analyzed using BD FacsDIVA
(Benton, Dickinson, and Company) and FlowJo software (Tree Star, Inc.).

Mutation of serotonin receptors
Calmodulin binding domains in the 5-HT2A receptor were mutated using a Qiagen sitedirected mutagenesis kit. All of the sites (F186, V193, F199, L382, and F391) were
mutated to alanine residues. Mutagenesis was previously performed by Dr. Melissa
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Maginnis. Following the transformation, plasmids were amplified and isolated using a
Qiagen Maxi Prep kit.

Transfection of mutated receptors
HEK293A cells were plated to 80% confluence in a 24 well plate at the time of
transfection. Before addition to the wells, 0.5µg/well of the receptor plasmids were mixed
in incomplete medium lacking serum or antibiotics. In a separate tube, 1µL/well of
Lipofectamine 2000 (L2000) (Thermo Fisher Scientific) was mixed with incomplete
medium lacking serum or antibiotics (Invitrogen). Plasmids and L2000 were incubated in
their respective tubes for 5 mins then before combined. Combined samples were mixed
well and incubated at room temperature for 15 mins. After incubation, 100µL were added
per well in a dropwise fashion and allowed to incubate in a humidified, 37ºC incubator
for 4 hrs. Following the incubation, the media was removed and 1mL of complete media
containing serum and antibiotics was added to cells. Transfection of plasmids was
allowed to progress for 24 hours before experimental use.

siRNA treatment
SVG-A cells were plated to approximately 50% confluence in 10% FBS MEM without
antibiotics in a 12 well plate. Cells were then allowed to adhere for 4 hrs before
transfection with siRNAs specific for AP2 (Dharmacon), b-arrestin (Cell Signaling
Technology), AP180 (ThermoFischer), clathrin heavy chain (Life technologies),
unconjugated non targeting control (Cell signaling technology 65685), or an EGF
receptor control (Cell Signaling Technology 64825). b-arrestin, clathrin heavy chain,
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AP180, and AP2 siRNA (30 or 60 pmol) was complexed with RNAiMax transfection
reagent (Invitrogen) in serum- and antibiotic-free MEM (Corning) and incubated at room
temperature (RT) for 10 mins. Transfection mixtures were added to cells incubated in
1mL of serum- and antibiotic-free MEM dropwise. Transfections were performed as
follows: b-arrestin siRNA: 30pmol for 72hrs; clathrin heavy chain siRNA: 30pmol for
24hrs, then washed in MEM and transfected with 30pmol for 48hrs; AP2 and AP180
siRNA (single or double transfections): 30pmol for 72hrs or 30pmol for 48hrs, then
washed in MEM and transfected with 30pmol for 24hrs for double transfection samples.
All siRNA transfections were allowed to proceed for 72hrs total prior to infection.
Transfection efficiency was monitored using Block-iT Alexa Fluor Red Control Oligo
(Life Technologies) visualized at 48 hrs post transfection by fluorescence microscopy.
Complexes were added to each well in 100µL volumes in a dropwise fashion and
incubated at 37ºC for 72 hrs; the transfection medium was not removed. At 72 hrs posttransfection, cells were infected with JCPyV or SV40 in MEM with 2% FBS and
incubated at 37ºC for 1 hour. Cells were fed with 1mL of complete MEM containing
antibiotics, incubated for 72 hrs, then fixed with 100% ice cold methanol and stained by
indirect immunofluorescence. The percentage of infected cells was quantified as
described previously.

siRNA western blot analysis
In order to analyze protein knockdown following siRNA treatment, SVG-A cells were
washed with PBS after a 72-hour treatment of the AP2 siRNA. Cells were scraped from
the wells and pelleted by centrifugation at 2500 rpm at 4ºC for 5min. Pellets were
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resuspended in 50µL of Tris-HCl lysis buffer that contained both protease (1:10) and
phosphate (1:100) inhibitors. Samples were incubated on ice for 10 mins before
centrifugation at 18,600 rpm at 4ºC for 10 mins. The supernatants were transferred to a
new tube and were mixed (1:1) with 2X Laemmli sample buffer containing
b-mercaptoethanol. Samples were resolved on a 10% SDS-PAGE TGX gel (BioRad) that
was run at 9 milliamps in a Bio-rad Mini gel box. Proteins were transferred to a
nitrocellulose membrane using the rapid blot transfer program on the Trans-Blot Turbo
Transfer System (BioRad). Membranes were blocked using 5% non-fat dry milk with
0.1% TBS-T overnight. Blots were then washed three times at RT for 10 mins with TBST (0.1% Tween) while vigorously rocking. Following washing, the blot was incubated
overnight while rocking at 4ºC with an antibody specific for AP2 (1:1000) (Cell
Signaling Technology) and polyclonal antibody for GAPDH (loading control) (1:2000)
(Abcam) in 5% BSA/ 0.1% TBS-T. Membranes were washed in TBS-T at RT, then
incubated with a secondary antibody at 1:15,000 (LICOR) dilution at RT for 1 hour in
5% milk with TBS-T. Membranes were washed in TBS-T and TBS, then imaged using a
LICOR Odyssey Clx. Results were quantified using the Image Studio program (LICOR).

Results
Clathrin inhibition decreases JCPyV infection
Previous studies have shown that chemical inhibition of the clathrin-mediated
endocytotic pathway reduces JCPyV infection (4,34). To further determine whether
clathrin-mediated endocytosis is crucial to infection, key proteins, including clathrin,
were targeted through siRNA treatment. SVG-A cells were transfected with a siRNA
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targeted toward clathrin heavy chain to
reduce clathrin protein levels in cells
(Fig. 6). Cells were then infected with
JCPyV and infection was quantitated by
indirect immunofluorescence in a viral
fluorescent focus unit (FFU) assay.
Cells expressing a clathrin siRNA
demonstrated an approximately 80%
decrease in infection in comparison to
cells treated with a control siRNA (Fig.
6). These data suggest that clathrin is
crucial for JCPyV infection.

Figure 6: Clathrin heavy chain siRNA limits
JCPyV infection. SVG-A cells were pretreated
with an siRNA specific to clathrin heavy chain
(CHC) or a control protein (EGFR). The cells were
then incubated for 72 hrs. Following this
incubation, cells were infected with JCPyV (MOI of
0.1FFU/cell). Infection was quantified by indirect
immunofluorescence using a VP1-specific antibody
at 72 hrs post infection. Data represent the average
percent infection for 5 fields of view for triplicate
samples; CHC siRNA in comparison to an siRNA
control. *,P <0.01 denotes significance determined
by students’ t-test.

The role of calmodulin in JCPyV infection is inconclusive
We hypothesized that the
interaction of calmodulin with the
5-HT2R plays a crucial role in
JCPyV infection. To investigate the
role of calmodulin in JCPyV
infection, SVG-A cells were
treated with a calmodulin
antagonist, calmidazolium
chloride, infected with JCPyV, and

Figure 7: Calmidazolium chloride limits JCPyV
infection. SVG-A cells at 90% confluency were pretreated
for 3 hours with a calmodulin antagonist at the
concentrations indicated. After treatment, cells were
infected for 72 hours with JCPyV (MOI of 1FFU/cells).
Cells were quantified by indirect immunofluorescence. Data
represent the average number of infected cells in a 10X field
for 5 visual fields. *, P <0.05 denotes significance
determined by students’ t test.
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infection was scored using an FFU assay. Cells treated with calmidazolium chloride led
to a significant decrease in infection at concentrations at or above 0.75-1µM (Fig. 7).
However, treating cells with concentrations greater than 1µM of calmidazolium chloride
did not result in a dose-dependent decrease in infection. This suggests that the antagonist
may have a secondary effect that is limiting infection, or the maximal efficacious
inhibitor concentration was reached without compromising cellular viability. An MTS
assay was performed to view cellular viability. There was a significant decrease in
cellular proliferation between a 0.75µM and 1µM treatment of calmidazolium chloride
(data not shown).
To further investigate the role of calmodulin, and to define direct calmodulinreceptor interactions, serotonin receptors with specific calmodulin binding domain
mutations were generated. Each of the key amino acids in the 1-8-14 and 1-10 motif of

Figure 8: 5-HT2 A receptor cell surface expression. HEK293A cells were transfected with the
transfection reagent (L2000) and the wild-type and mutant 5-HT2ARs for 24 hours. After transfection,
the cells were stained with a 5-HT2A specific antibody and complementary secondary fluorescent
antibody. Fluorescence was quantified by flow cytometry. Histograms represent the median
fluorescence intensity for 10,000 events.
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the 5-HT2A receptor, F186, F199, V193, L382, and F391, were mutated to alanine. The
serotonin receptors with mutated CaM-binding domains were transfected into HEK293A,
a poorly permissive cell line. Previous research by the Maginnis Lab has shown that
when the mutated receptors were transfected into HEK293A cells then infected with
JCPyV there was a significant decrease in infection in the F391A mutant receptor yet no
difference in infection was observed for other mutations tested (Maginnis Lab,
unpublished data). To determine if this decrease was due to a lack of calmodulin binding
or a decrease in the ability of the receptor to be expressed on the cell surface, the cell
surface expression of the mutated receptors was analyzed. HEK293A cells were
transfected with the wild-type and mutant 5-HT2A receptors and stained with a serotoninspecific antibody and complementary secondary fluorescent antibody, and cell surface
expression of the receptor was determined by flow cytometry. All of the mutated
receptors were expressed on the cell surface at levels greater than the vehicle control
(L2000) but at levels that were lower than the wild type 5-HT2A receptor (Fig. 8). The
mutated receptor had reduced cell-surface expression in comparison to the wild-type 5HT2A receptor, and (F391A) was the only receptor that had a decreased infection (Fig. 8.
and Maginnis Lab, unpublished data). Thus, the decrease in infection in cells expressing
the F391A mutant could be due to reduced surface expression of the receptor. Taken
together, these data are not sufficient to determine whether calmodulin is crucial to
JCPyV infection, and the role of other scaffolding proteins involved in CME were further
explored.
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siRNA targeting of b-arrestin, AP2, and AP180 significantly decreases JCPyV
infection
b-arrestin binds to the 5-HT2R b-arrestin domain, then scaffolds and recruits AP2,
AP180, and clathrin (18). It also plays an important role in the uncoupling of G proteins
from serotonin receptors (18). This
data suggests that b-arrestin may play
a crucial role in JCPyV entry in a
clathrin-mediated endocytic manner.
To explore this further, SVG-A cells
were transfected with a siRNA
specific to b-arrestin and infected
with JCPyV or SV40 polyomavirus
as a control (Fig. 9). Cells treated
with the b-arrestin siRNA
demonstrated an 80% decrease in

Figure 9: β-arrestin limits JCPyV infection. SVGA cells were pretreated with a siRNA oligo specific
to clathrin heavy chain (CHC) or control (EGFR).
The cells were then incubated for 72 hrs. Following
this incubation, cells were infected with JCPyV or
SV40 (MOI of 0.1 or 0.0001FFU/cell respectively)
for 72 hrs. Data represent the average percentage of
infected cells per visual field for five visual fields for
β-arrestin siRNA in comparison to a siRNA control.
*, P <0.01 denotes significance determined by
students’ t test.

JCPyV infection compared to cells expressing a control siRNA, while no significant
reduction was noted in the SV40 infection (Fig. 9). These data suggest that b-arrestin is
crucial to JCPyV infection and that JCPyV enters host cells in a clathrin-mediated
pathway that is distinct from the SV40 endocytotic pathway.
To further demonstrate that JCPyV uses clathrin-mediated endocytosis, an AP2specific siRNA was used to reduce AP2 expression. Cells were transfected with the AP2
siRNA, followed by infection with JCPyV or SV40 (Fig. 10A), resulting in a ~70%
decrease in JCPyV infection in cells treated with an AP2 siRNA compared to cells treated
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with a control siRNA (Fig. 10A). Comparatively, SV40 infection was not impacted in
cells that were treated with an AP2-specific siRNA or a control siRNA. These data
suggest that AP2 is also crucial for JCPyV infection.
To confirm that the AP2 siRNA was specifically reducing the levels of AP2
protein in the cell, a western blot was performed (Fig. 10B). SVG-A cells were treated
with an AP2-specific siRNA or a control siRNA and cell lysates were resolved by SDSA

B

Figure 10: AP2 degraded by siRNA significantly impacts JCPyV infection. (A) SVG-A cells were
pretreated with a siRNA oligo specific to AP2 or control (EGFR). The cells were then incubated for 72
hrs. Following this incubation, cells were infected with either JCPyV or SV40 (MOI of 0.1 and .000l
FFU/cell respectively) and infection was allowed to progress for 72 hrs. Data represent the average
percentage of infected cells per visual field for five visual fields for AP2 siRNA in comparison to a siRNA
control. (B) SVG-A cells were pretreated with an AP2-specific siRNA for 72hrs in a 6 well plate.
Following incubation, proteins were run on a SDS page gel and stained with a secondary antibody for
AP2 or GAPDH (control). *, P <0.01 denotes significance determined by students’ t test.

PAGE and analyzed by western blot using an antibody specific to AP2 or a control
GAPDH and complementary secondary antibodies. Protein levels were quantified using a
LiCOR Odyssey Clx, and there was a 75% decrease in AP2 protein in the cells treated
with the AP2 siRNA compared to cells treated with the control siRNA (Fig. 10B). This
data suggests that the siRNA for AP2 is working properly and degrading the AP2 protein.
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To explore the impact of AP180 in an absence or presence of AP2 in JCPyV
infection, cells were transfected with an AP2 siRNA, AP180 siRNA, or a mixture of both
siRNAs (Fig. 11). It was observed
that the AP180 siRNA had a 60%
decrease in infection and the AP2
siRNA had a 35% decrease in
infection when compared to a
control siRNA (Fig. 11). The dual
siRNA treatment had the most
significant effect on infection and
decreased infection by 80% when
compared to a control siRNA.
These results indicate that while

Figure 11: Dual AP2 and AP180 siRNA treatment
limits JCPyV infection. SVG-A cells were treated with an
siRNA specific for AP2, AP180, or both (AP180 and AP2),
or control (EGFR) for 72 hrs. Following incubation, cells
were infected with JCPyV (MOI of 0.1FFU/cell) for 72
hrs. Infection was quantified as percent infection for the
AP2-, AP180-, or dual-siRNA treatment in comparison to
a siRNA control *,P <0.01, denotes significance
determined by students’ t test.

both adaptor proteins are required for infection, the impact of AP180 is greater than that
of AP2. Additionally, this further suggests that AP2 and AP180 are crucial to JCPyV
infection and that AP2 and AP180 may act in a collaborative fashion because an additive
effect was observed. These data suggest that JCPyV requires AP2 and AP180 for
successful infection of human glial cells.

Discussion
JCPyV was previously shown to require the activity of 5-HT2R serotonin
receptors for viral entry into host cells (4). Furthermore, evidence has demonstrated that
JCPyV entry occurs in a clathrin-dependent manner (4). However, the evidence that led
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to the conclusion that JCPyV enters cells by clathrin-mediated endocytosis is based on
the finding that chlorpromazine can inhibit JCPyV infection (23). While chlorpromazine
is widely used in the field of virology to limit clathrin-mediated endocytosis, it is also a
5-HT2R serotonin receptor antagonist (23) and is thus not an appropriate inhibitor for use
in JCPyV studies. Therefore, the mechanism of JCPyV entry required further
investigation using more specific inhibitors and additional methods to determine whether
clathrin and related scaffolding proteins are essential for JCPyV entry into host cells.
Herein, I have demonstrated that JCPyV infection is dependent upon clathrin, as
evidenced by a significant reduction in JCPyV infection in cells treated with an siRNA
directed toward clathrin heavy chain (Fig. 6). Though calmodulin is thought to play a role
in uncoupling the classical GPCR G-protein signaling pathway and activating a b-arrestin
specific endocytic pathway, inhibition of calmodulin by a chemical inhibitor did not have
a significant effect on JCPyV infection (Fig. 7), indicating that calmodulin may not be
involved in JCPyV infection and requires further exploration. However, gene silencing of
b-arrestin, a scaffolding protein that can bind directly to 5-HT2Rs, and other scaffolding
proteins essential for clathrin-mediated endocytosis including AP2 and AP180,
significantly prevented viral infection (Fig. 9, 10, and 11), indicating that JCPyV utilizes
clathrin-mediated endocytosis to infect host cells.
Despite previous evidence that calmodulin plays a role in JCPyV infection
(Maginnis Lab, unpublished results), we found conflicting results that render our data
inconclusive. We investigated the role of calmodulin in JCPyV infection as it has been
previously reported that calmodulin binding to the serotonin receptor activates the
receptor and plays a role in endocytosis and activation of signaling events (18,19).
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However, treatment of cells with the inhibitor calmidazolium chloride led to a decrease in
JCPyV infection, yet the reduction in infection was not dose-dependent (Fig. 7). An MTS
toxicity assay revealed that calmidazolium chloride was toxic to the cells at higher
concentrations (data not shown). Therefore, the chosen inhibitor was not acting as
expected and was most likely having secondary effects, or high enough concentrations
necessary to inhibit calmodulin were not obtainable due to cellular toxicity effects.
Further, we demonstrated that a decrease in infection could be achieved by mutating the
phenylalanine at position 391 to an alanine (F391A), but this receptor was shown to have
reduced cell surface expression by flow cytometry compared to the wild type 5-HT2AR
receptor (Fig. 8). This indicates that the decrease in infection demonstrated by the F391A
mutant could be due to a loss of calmodulin interaction or that there are fewer receptors
on the surface that could be utilized for entry. Taken together, these data are not
conclusive to determine the role of calmodulin in JCPyV entry. To further define the role
of calmodulin in JCPyV infection, an additional chemical inhibitor that limits calmodulin
in the cell should be explored. Additionally, further research should be conducted into the
residues that interact with calmodulin by making multiple mutations, instead of single
point mutations in 5-HT2AR.
We also demonstrated that JCPyV uses a clathrin mediated-endocytic entry
pathway as gene silencing of key scaffolding proteins involved in 5-HT2R internalization,
b-arrestin, AP2, AP180, and clathrin, significantly reduced infection. Interestingly, cells
that received a double AP2 siRNA treatment (Fig. 10A) had an even greater decrease in
JCPyV infection and cellular toxicity than those that received a single treatment of AP2
or AP180 siRNA (Fig. 11). This observed effect could be due to the fact that a double
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transfection of siRNA against the AP2 µ2 subunit causes the knockdown of the alpha and
beta appendages that interact with AP180, which has been previously demonstrated in the
literature (37). This indicates that the significant decrease in a dual siRNA treatment of
AP2 could be due to the limitation of both AP2 and AP180 rather than just AP2. Taken
together, these data suggest that JCPyV is utilizing a mechanism for entry similar to that
of the activated 5-HT2R receptor.
The closely related polyomavirus, SV40, was used as a control, and treatment of
cells with siRNAs specific for b-arrestin, AP2, AP180, and clathrin, had no effect on
SV40 infection (Fig. 9 and 10. and not shown data.) This confirms that the activation of
clathrin-mediated endocytosis in SVG-A cells is specific for JCPyV as it differs from a
close viral relative. This data further aids our understanding of the processes involved in
JCPyV entry and, more broadly, how viruses are able to enter cells. Future studies will
focus on defining the role of other 5-HT2R clathrin mediated endocytic proteins in
JCPyV infection and exploring whether inhibition of these scaffolding proteins plays
roles in the ability of the virus to bind to host cells.
b-arrestin mediated endocytosis has been shown to lead to the activation of
signaling events, including those in the MAPK pathway. MAPK signaling can then lead
to the activation of another group of signaling proteins, extracellular–signal regulated
kinases (ERK). The Maginnis Laboratory has previously demonstrated that ERK is
crucial to JCPyV infection (Dushane et al., submitted manuscript). Because b-arrestin has
been implicated as an activator of ERK in other studies, this further suggests that barrestin aids in JCPyV entry in a clathrin-mediated entry process and the activation of
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scaffolding proteins at the time of entry may be impacting activation of downstream
signaling cascades crucial for the JCPyV infectious lifecycle.
The data presented in this thesis demonstrates the entry mechanism utilized by
JCPyV in SVG-A cells.
Based on the reported
findings, we have generated
a working model for JCPyV
entry (Fig. 12). Upon viral
activation of the 5-HT2R, barrestin binds to the receptor,
likely causing the uncoupling

Figure 12: Model of JCPyV entry. b-arrestin binding to the 5HT2Rs recruits the scaffolding protein AP2 and AP180. AP2 and
AP180 act to recruit clathrin. Clathrin mediates endocytosis of
the receptor and JCPyV into the cell.

of the G-proteins, which
leads to receptor desensitization and subsequent internalization. b-arrestin causes further
recruitment of scaffolding proteins AP2, and AP180, which lead to the recruitment of
clathrin. AP2 and AP180 have been reported to act in cooperation to recruit and stabilize
clathrin at the plasma membrane. Collectively, the presence of these proteins within the
cell are crucial to JCPyV entry into permissive host cells.
In recent years, the incidence of PML has increased in the HIV/AIDS population
and those undergoing immunosuppression therapies for immunological disorders, such as
multiple sclerosis (8). If left untreated, PML is a rapidly fatal, devastating disease.
Treatment options for PML are currently ineffective and inadequate, and sometimes lead
to the patient’s condition worsening (7,8). In order to develop effective therapies, the
scientific community must first understand the mechanisms of JCPyV entry, as it
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illuminates targets for potential antiviral therapeutics. The present study provides new
information confirming that JCPyV enters through clathrin-mediated endocytosis and that
key scaffolding proteins for receptor internalization, b-arrestin, AP2, AP180, and
clathrin, are also crucial to JCPyV entry.
These proteins can serve as new targets for therapeutics to prevent PML.
Approximately 25% to 30% of drugs on the market utilize GPCRs as a target (35). The
mechanism of many of these treatments, including the SSRI drugs and GPCR-targeting
drugs that have been utilized for treatment in PML, is still unknown. The present research
contributes to efforts to produce efficacious drugs by determining that b-arrestin, AP2,
AP180, and clathrin are crucial to JCPyV entry, thus providing new targets for potential
treatments. Indeed, some of the b-blocker class of GPCR-targeting drugs on the market,
such as Nebivolol, have been shown to specifically target b-arrestin (39). Drugs like
these give us confidence that understanding the biological basis of viral entry,
specifically the role of scaffolding proteins like b-arrestin, can optimize treatment
efficacy. Thus, if we are able to contribute to the design of a new drug that has the
potential to limit JCPyV entry and subsequent spread of the virus, the incidence of PML
may be reduced. For example, a b-arrestin- or 5-HT2R-specific drug could be combined
with mefloquine, an anti-malarial drug that has demonstrated decreased JCPyV infection
at a post-entry step (24), in a dual therapy paradigm to limit the progression or
development of PML. This treatment option could not only lead to cognitive
improvements in patients with PML, but also ultimately reduce the number of cases of
PML that develop; it has been demonstrated that dual treatments of mefloquine with a
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serotonin antagonist have, in some cases, reduced PML symptoms and JCPyV presence
in the CSF (39).
Collectively, this data has provided new information about the relationship
between virus-to-host interactions during viral entry. This research contributes not only to
the understanding of the fatal JCPyV infection, but it can also be applied to a broader
understanding of viral pathogenesis and its implications in human disease, ultimately
leading to the development of effective therapeutics against opportunistic viral
pathogens.
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